Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved

cancer, biological markers, phase 1 clinical trials, drug approval, medical oncology, united states food and drug administration guidelines, adverse event, national comprehensive cancer network, American society of clinical oncology

Phase I oncology trials are often considered a therapeutic option, but this claim is primarily based on surrogate measures like objective response rates. A systematic search was conducted to evaluate the therapeutic value of phase I cancer trial participation, focusing on the likelihood of patien…

Apr 1^st • 14 mins read

Are the chronological age cutoffs used in clinical oncology guidelines biologically meaningful?

Age, cutoffs, clinical oncology guide, biomarkerslines

Age is a significant risk factor for cancer, influencing tumour biology, treatment recommendations, and therapy response. Breast cancer incidence peaks around 70 years of age, with over one-third of diagnoses in this age group. Clinical guidelines vary in defining "older" patients, using …

Dec 1^st • 4 mins read